NewAmsterdam Reports Net Loss of $203.8 Million for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy NAMS?
Net loss for the year ended December 31, 2025, was $203.8 million, compared to net loss of $241.6 million in the year ended December 31, 2024. "2025 marked a year of meaningful clinical and regulatory progress for NewAmsterdam, as we advanced our mission to bring a potentially transformative therapy with obicetrapib to cardiometabolic disease patients who continue to struggle to reach their LDL-C goals," said Michael Davidson, CEO. "Marketing Authorization Applications for obicetrapib and the fixed dose combination were accepted for review by the European Medicines Agency, Switzerland, and United Kingdom regulators, and we anticipate a decision from each in the second half of 2026. In parallel, together with our partner Menarini, we are actively preparing for a potential commercial launch in Europe. In the United States, we continue to expand our commercial capabilities with the notable hiring of Steve Albers, former senior vice president of market access and public affairs at Novo Nordisk, who will now lead our market access and public affairs efforts, further strengthening our established team. At the same time, we remain focused and well positioned to execute our clinical development strategy, including the advancement of obicetrapib in our three ongoing Phase 3 trials: PREVAIL, REMBRANT and RUBENS. In December 2025, we initiated the RUBENS trial, which will evaluate obicetrapib alone and in combination with ezetimibe in patients with type 2 diabetes or metabolic syndrome that require additional lowering of LDL-C despite treatment with available therapy, with topline data expected by year-end 2026. Our PREVAIL cardiovascular outcomes trial continues to progress well, where the overall blinded MACE event rate in PREVAIL through the initial 12-months was in line with what we observed in BROADWAY. NewAmsterdam continues to operate from a position of financial strength, with cash runway expected to be sufficient to fund operations through the PREVAIL readout and, if approved, support the subsequent U.S. commercial launch. Additionally, following positive biomarker results from the Alzheimer's disease analysis in the BROADWAY trial, we plan to initiate a new clinical trial evaluating obicetrapib in early Alzheimer's disease patients this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAMS
Wall Street analysts forecast NAMS stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.770
Low
37.00
Averages
48.63
High
60.00
Current: 30.770
Low
37.00
Averages
48.63
High
60.00
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule 5635(c)(4): The article discusses the specific NASDAQ listing rule that governs the issuance of inducement grants to attract and retain talent.
See More
NewAmsterdam Pharma Releases FY 2025 Financial Results
- Annual Revenue Performance: NewAmsterdam Pharma reported FY 2025 revenue of $22.5 million, indicating growth; however, the overall financial situation remains challenging, reflecting competitive pressures in the market.
- Net Loss Improvement: The net loss for 2025 was $203.8 million, an improvement from $241.6 million in 2024, suggesting progress in cost control and operational efficiency.
- Cash Flow Status: As of December 31, 2025, NewAmsterdam's cash, cash equivalents, and marketable securities totaled $728.9 million, down from $834.2 million in 2024, indicating pressure on the company's financial management.
- Market Outlook Analysis: Despite improvements in financial data, ongoing net losses and declining cash flow may affect investor confidence, necessitating effective strategies from NewAmsterdam to enhance market competitiveness and financial health.
See More
NewAmsterdam Pharma Reports Clinical Progress and Financial Update
- Regulatory Approval Progress: NewAmsterdam Pharma's Marketing Authorization Applications for obicetrapib and its fixed-dose combination with ezetimibe have been accepted by EMA, UK, and Swiss regulators, with approval decisions expected in the second half of 2026, laying the groundwork for market entry in the cardiovascular disease sector.
- Clinical Trial Data: Topline data from the RUBENS Phase 3 trial is anticipated by the end of 2026, evaluating the efficacy of obicetrapib in patients with type 2 diabetes and metabolic syndrome requiring further LDL-C reduction, which could enhance the company's competitive position in the cardiovascular drug market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported $728.9 million in cash, cash equivalents, and marketable securities, a decrease from 2024, yet sufficient to fund operations through the PREVAIL trial readout and potential U.S. market launch.
- R&D Expense Changes: R&D expenses for 2025 were $141.8 million, down from $151.4 million in 2024, primarily due to the completion of several Phase 3 clinical trials, indicating effective cost control and resource optimization by the company.
See More
NAMS Options Analysis: $30 Put Contract Offers Attractive Yield Boost
- Put Option Appeal: The $30.00 put option for NAMS has a current bid of 20 cents, and if an investor sells this contract, they commit to buying shares at $30.00, effectively lowering their cost basis to $29.80, which is about a 6% discount from the current price of $31.77, making it attractive for those looking to enter at a lower price.
- Yield Potential: Should the put option expire worthless, it would yield a 0.67% return on cash commitment, or an annualized yield of 3.86%, referred to as YieldBoost, highlighting the potential profitability of this contract.
- Call Option Returns: The $35.00 call option has a current bid of 40 cents, and if an investor buys shares at $31.77 and sells this call, they could achieve a total return of 11.43% if the stock is called away at expiration, showcasing the potential upside of this strategy.
- Risk Assessment: Current analytics suggest a 65% chance that the $30 put option will expire worthless, while the $35 call option has a 56% chance of doing the same, indicating that investors should carefully weigh the risks and rewards when selecting their options strategies.
See More
NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26
- Clinical Trial Progress: NewAmsterdam Pharma has enrolled its first patient in the RUBENS Phase 3 trial initiated in December 2025, which is expected to provide new treatment options for patients with metabolic syndrome, thereby enhancing the company's competitive position in the cardiovascular disease market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported a cash, cash equivalents, and marketable securities balance of approximately $729 million, which is sufficient to fund operations through the anticipated readout of the PREVAIL trial, ensuring future commercialization potential.
- Regulatory Advancements: The company is advancing its EMA applications for obicetrapib and its fixed-dose combination with Menarini, with an expected approval decision in 2H26, which will lay the groundwork for commercialization in the European market.
- Clear Strategic Goals: NewAmsterdam plans to initiate a clinical trial for Alzheimer's disease in 2026, further expanding the indications for obicetrapib, demonstrating the company's strategic positioning in both cardiovascular and neurodegenerative disease sectors.
See More
NewAmsterdam Grants 40,000 Share Options to Attract New Hires
- Employee Incentive Plan: NewAmsterdam Pharma's Board Compensation Committee approved the grant of 40,000 inducement share options to two non-executive new hires, aimed at attracting talent and strengthening the team in line with the 2024 Inducement Plan.
- Option Details: The options have an exercise price of $39.61 per share, based on the closing price on December 1, 2025, and will vest over four years, designed to incentivize long-term employee commitment to the company.
- Market Reaction: This move not only enhances employee loyalty and motivation but may also attract more top talent in the future, thereby strengthening the company's competitiveness and innovation capabilities.
- Strategic Significance: By implementing the inducement option plan, NewAmsterdam demonstrates its commitment to talent, aiming to fill the market gap in cardiovascular disease treatment and drive long-term growth in the biopharmaceutical industry.
See More
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule 5635(c)(4): The article discusses the specific NASDAQ listing rule that governs the issuance of inducement grants to attract and retain talent.
See More
NewAmsterdam Pharma Releases FY 2025 Financial Results
- Annual Revenue Performance: NewAmsterdam Pharma reported FY 2025 revenue of $22.5 million, indicating growth; however, the overall financial situation remains challenging, reflecting competitive pressures in the market.
- Net Loss Improvement: The net loss for 2025 was $203.8 million, an improvement from $241.6 million in 2024, suggesting progress in cost control and operational efficiency.
- Cash Flow Status: As of December 31, 2025, NewAmsterdam's cash, cash equivalents, and marketable securities totaled $728.9 million, down from $834.2 million in 2024, indicating pressure on the company's financial management.
- Market Outlook Analysis: Despite improvements in financial data, ongoing net losses and declining cash flow may affect investor confidence, necessitating effective strategies from NewAmsterdam to enhance market competitiveness and financial health.
See More
NewAmsterdam Pharma Reports Clinical Progress and Financial Update
- Regulatory Approval Progress: NewAmsterdam Pharma's Marketing Authorization Applications for obicetrapib and its fixed-dose combination with ezetimibe have been accepted by EMA, UK, and Swiss regulators, with approval decisions expected in the second half of 2026, laying the groundwork for market entry in the cardiovascular disease sector.
- Clinical Trial Data: Topline data from the RUBENS Phase 3 trial is anticipated by the end of 2026, evaluating the efficacy of obicetrapib in patients with type 2 diabetes and metabolic syndrome requiring further LDL-C reduction, which could enhance the company's competitive position in the cardiovascular drug market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported $728.9 million in cash, cash equivalents, and marketable securities, a decrease from 2024, yet sufficient to fund operations through the PREVAIL trial readout and potential U.S. market launch.
- R&D Expense Changes: R&D expenses for 2025 were $141.8 million, down from $151.4 million in 2024, primarily due to the completion of several Phase 3 clinical trials, indicating effective cost control and resource optimization by the company.
See More
NAMS Options Analysis: $30 Put Contract Offers Attractive Yield Boost
- Put Option Appeal: The $30.00 put option for NAMS has a current bid of 20 cents, and if an investor sells this contract, they commit to buying shares at $30.00, effectively lowering their cost basis to $29.80, which is about a 6% discount from the current price of $31.77, making it attractive for those looking to enter at a lower price.
- Yield Potential: Should the put option expire worthless, it would yield a 0.67% return on cash commitment, or an annualized yield of 3.86%, referred to as YieldBoost, highlighting the potential profitability of this contract.
- Call Option Returns: The $35.00 call option has a current bid of 40 cents, and if an investor buys shares at $31.77 and sells this call, they could achieve a total return of 11.43% if the stock is called away at expiration, showcasing the potential upside of this strategy.
- Risk Assessment: Current analytics suggest a 65% chance that the $30 put option will expire worthless, while the $35 call option has a 56% chance of doing the same, indicating that investors should carefully weigh the risks and rewards when selecting their options strategies.
See More
NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26
- Clinical Trial Progress: NewAmsterdam Pharma has enrolled its first patient in the RUBENS Phase 3 trial initiated in December 2025, which is expected to provide new treatment options for patients with metabolic syndrome, thereby enhancing the company's competitive position in the cardiovascular disease market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported a cash, cash equivalents, and marketable securities balance of approximately $729 million, which is sufficient to fund operations through the anticipated readout of the PREVAIL trial, ensuring future commercialization potential.
- Regulatory Advancements: The company is advancing its EMA applications for obicetrapib and its fixed-dose combination with Menarini, with an expected approval decision in 2H26, which will lay the groundwork for commercialization in the European market.
- Clear Strategic Goals: NewAmsterdam plans to initiate a clinical trial for Alzheimer's disease in 2026, further expanding the indications for obicetrapib, demonstrating the company's strategic positioning in both cardiovascular and neurodegenerative disease sectors.
See More
NewAmsterdam Grants 40,000 Share Options to Attract New Hires
- Employee Incentive Plan: NewAmsterdam Pharma's Board Compensation Committee approved the grant of 40,000 inducement share options to two non-executive new hires, aimed at attracting talent and strengthening the team in line with the 2024 Inducement Plan.
- Option Details: The options have an exercise price of $39.61 per share, based on the closing price on December 1, 2025, and will vest over four years, designed to incentivize long-term employee commitment to the company.
- Market Reaction: This move not only enhances employee loyalty and motivation but may also attract more top talent in the future, thereby strengthening the company's competitiveness and innovation capabilities.
- Strategic Significance: By implementing the inducement option plan, NewAmsterdam demonstrates its commitment to talent, aiming to fill the market gap in cardiovascular disease treatment and drive long-term growth in the biopharmaceutical industry.
See More
